Intro

This chapter explores the recent challenges faced by Novo Nordisk as its shares reach an 18-month low amid new drug price negotiations. It examines the broader implications for the obesity drug market and potential future strategies in response to evolving pricing pressures and competition.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.